• 1
    Giles FJ, O'Brien SM, Keating MJ. Chronic lymphocytic leukemia in (Richter's) transformation. Semin Oncol. 1998; 25: 117125.
  • 2
    Robertson LE, Pugh W, O'Brien S, et al. Richter's syndrome: a report on 39 patients. J Clin Oncol. 1993; 11: 19851989.
  • 3
    Keating MJ, O'Brien S, Kantarjian H, et al. Long-term follow-up of patients with chronic lymphocytic leukemia treated with fludarabine as a single agent. Blood. 1993; 81: 28782884.
  • 4
    Harousseau JL, Flandrin G, Tricot G, et al. Malignant lymphoma supervening in chronic lymphocytic leukemia and related disorders. Richter's syndrome: a study of 25 cases. Cancer. 1984; 48: 13021308.
  • 5
    Foucar K, Rydell RE. Richter's syndrome in chronic lymphocytic leukemia. Cancer. 1980; 46: 118134.
  • 6
    Cabanillas F. Experience with salvage regimens at M. D. Anderson Hospital. Ann Oncol. 1991; 2 (Suppl 1): 3132.
  • 7
    Trump DL, Mann RB, Phelps R, et al. Richter's syndrome: diffuse histiocytic lymphoma in patients with chronic lymphocytic leukemia. A report of five cases and review of the literature. Am J Med. 1980; 68: 539548.
  • 8
    Giles FJ, O'Brien SM, Santini V, et al. Sequential cis-platinum and fludarabine with or without arabinosyl cytosine in patients failing prior fludarabine therapy for chronic lymphocytic leukemia: a Phase II study. Leuk Lymphoma. 1999; 36: 5765.
  • 9
    Tsimberidou A, O'Brien S, Cortes J, et al. Phase II study of fludarabine, cytarabine (ara-c), cyclophosphamide, cisplatin and GM-CSF in patients with Richter's syndrome or refractory lymphoproliferative disorders. Leuk Lymphoma. 2002; 43: 767772.
  • 10
    Murphy SB, Bowman WP, Abromowitch M, et al. Results of treatment of advanced-stage Burkitt's lymphoma and B cell (SIg+) acute lymphoblastic leukemia with high-dose fractionated cyclophosphamide and coordinated high-dose methotrexate and cytarabine. J Clin Oncol. 1986; 4: 17321739.
  • 11
    Kantarjian HM, O'Brien S, Smith TL, et al. Results of treatment with hyper-CVAD, a dose-intensive regimen, in adult acute lymphocytic leukemia. J Clin Oncol. 2000; 18: 547561.
  • 12
    Garcia-Manero G, Kantarjian HM. The hyper-CVAD regimen in adult acute lymphocytic leukemia. Hematol Oncol Clin North Am. 2000; 14: 13811396.
  • 13
    Faderl S, Kantarjian HM, Thomas DA, et al. Outcome of Philadelphia chromosome-positive adult acute lymphoblastic leukemia. Leuk Lymphoma. 2000; 36: 263273.
  • 14
    Koller CA, Kantarjian HM, Thomas D, et al. The hyper-CVAD regimen improves outcome in relapsed acute lymphoblastic leukemia. Leukemia. 1997; 11: 20392044.
  • 15
    Dimopoulos MA, Weber D, Delasalle KB, et al. Combination therapy with interferon-dexamethasone for newly diagnosed patients with multiple myeloma. Cancer. 1993; 72: 25892592.
  • 16
    Khouri IF, Romaguera J, Kantarjian H, et al. Hyper-CVAD and high-dose methotrexate/cytarabine followed by stem-cell transplantation: an active regimen for aggressive mantle-cell lymphoma. J Clin Oncol. 1998; 16: 38033809.
  • 17
    Romaguera JE, Khouri IF, Kantarjian HM, et al. Untreated aggressive mantle cell lymphoma: results with intensive chemotherapy without stem cell transplant in elderly patients. Leuk Lymphoma. 2000; 39: 7785.
  • 18
    Cortes J, Thomas D, Rios A, et al. Hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone and highly active antiretroviral therapy for patients with acquired immunodeficiency syndrome-related Burkitt lymphoma/leukemia. Cancer. 2002; 94: 14921499.
  • 19
    Thomas DA, Cortes J, O'Brien S, et al. Hyper-CVAD program in Burkitt's-type adult acute lymphoblastic leukemia. J Clin Oncol. 1999; 17: 24612470.
  • 20
    Dabaja B, O'Brien S, Kantarjian H, et al. Fractionated cyclophosphamide, vincristine, liposomal daunorubicin (DaunoXome), and dexamethasone (hyperCVXD) regimen in Richter's syndrome. Leuk Lymphoma. 2001; 42: 329338.
  • 21
    Richardson DS, Kelsey SM, Johnson SA, et al. Early evaluation of liposomal daunorubicin (DaunoXome, Nexstar) in the treatment of relapsed and refractory lymphoma. Invest New Drugs. 1997; 15: 247253.
  • 22
    Flinn IW, Goodman SN, Post L, et al. A dose-finding study of liposomal daunorubicin with CVP (COP-X) in advanced NHL. Ann Oncol. 2000; 11: 691695.
  • 23
    McBride NC, Cavenagh JD, Ward MC, et al. Liposomal daunorubicin (DaunoXome) in combination with cyclophosphamide, vincristine and prednisolone (COP-X) as salvage therapy in poor-prognosis non-Hodgkins lymphoma. Leuk Lymphoma. 2001; 42: 8998.
  • 24
    Janknegt R. Liposomal formulations of cytotoxic drugs. Support Care Cancer. 1996; 4: 298304.
  • 25
    Muggia FM. Liposomal encapsulated anthracyclines: new therapeutic horizons. Curr Oncol Rep. 2001; 3: 156162.
  • 26
    Forssen EA, Male-Brune R, Adler-Moore JP, et al. Fluorescence imaging studies for the disposition of daunorubicin liposomes (DaunoXome) within tumor tissue. Cancer Res. 1996; 56: 20662075.
  • 27
    Czuczman MS, Grillo-Lopez AJ, White CA, et al. Treatment of patients with low-grade B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and CHOP chemotherapy. J Clin Oncol. 1999; 17: 268276.
  • 28
    Vose JM, Link BK, Grossbard ML, et al. Phase II study of rituximab in combination with chop chemotherapy in patients with previously untreated, aggressive non-Hodgkin's lymphoma. J Clin Oncol. 2001; 19: 389397.
  • 29
    Cheson BD. CHOP plus rituximab—balancing facts and opinion. N Engl J Med. 2002; 346: 280282.
  • 30
    Coiffier B, Lepage E, Briere J, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med. 2002; 346: 235242.
  • 31
    Wilson WH, Gutierrez M, O'Connor P, et al. The role of rituximab and chemotherapy in aggressive B-cell lymphoma: a preliminary report of dose-adjusted EPOCH-R. Semin Oncol. 2002; 29: 4147.
  • 32
    Keating MJ, O'Brien S, Albitar M. Emerging information on the use of rituximab in chronic lymphocytic leukemia. Semin Oncol. 2002; 29: 7074.
  • 33
    Ghielmini M, Schmitz SF, Burki K, et al. The effect of rituximab on patients with follicular and mantle-cell lymphoma. Swiss Group for Clinical Cancer Research (SAKK). Ann Oncol. 2000; 11: 123126.
  • 34
    Foran JM, Cunningham D, Coiffier B, et al. Treatment of mantle-cell lymphoma with rituximab (chimeric monoclonal anti-CD20 antibody): analysis of factors associated with response. Ann Oncol. 2000; 11: 117121.
  • 35
    Chow KU, Sommerlad WD, Boehrer S, et al. Anti-CD20 antibody (IDEC-C2B8, rituximab) enhances efficacy of cytotoxic drugs on neoplastic lymphocytes in vitro: role of cytokines, complement, and caspases. Haematologica. 2002; 87: 3343.
  • 36
    Demidem A, Lam T, Alas S, et al. Chimeric anti-CD20 (IDEC-C2B8) monoclonal antibody sensitizes a B cell lymphoma cell line to cell killing by cytotoxic drugs. Cancer Biother Radiopharm. 1997; 12: 177186.
  • 37
    Stockmeyer B, Elsasser D, Dechant M, et al. Mechanisms of G-CSF- or GM-CSF-stimulated tumor cell killing by Fc receptor-directed bispecific antibodies. J Immunol Methods. 2001; 248: 103111.
  • 38
    Chaperot L, Chokri M, Jacob MC, et al. Differentiation of antigen-presenting cells (dendritic cells and macrophages) for therapeutic application in patients with lymphoma. Leukemia. 2000; 14: 16671677.
  • 39
    Chow KU, Schneider B, Mitrou PS, et al. Influence of various cytokines on the expression of CD20 on the surface of CLL-cells in vitro. Leuk Res. 2001; 25: 99100.
  • 40
    The International Non-Hodgkin's Lymphoma Prognostic Factors Project. A predictive model for aggressive non-Hodgkin's lymphoma. N Engl J Med. 1993; 329: 987994.
  • 41
    Howard OM, Gribben JG, Neuberg DS, et al. Rituximab and CHOP induction therapy for newly diagnosed mantle-cell lymphoma: molecular complete responses are not predictive of progression-free survival. J Clin Oncol. 2002; 20: 12881294.
  • 42
    Huhn D, von Schilling C, Wilhelm M, et al. Rituximab therapy of patients with B-cell chronic lymphocytic leukemia. Blood. 2001; 98: 13261331.
  • 43
    Dillman RO. Infusion reactions associated with the therapeutic use of monoclonal antibodies in the treatment of malignancy. Cancer Metastasis Rev. 1999; 18: 465471.
  • 44
    Byrd JC, Waselenko JK, Maneatis TJ, et al. Rituximab therapy in hematologic malignancy patients with circulating blood tumor cells: association with increased infusion-related side effects and rapid blood tumor clearance. J Clin Oncol. 1999; 17: 791795.
  • 45
    O'Brien SM, Kantarjian H, Thomas DA, et al. Rituximab dose-escalation trial in chronic lymphocytic leukemia. J Clin Oncol. 2001; 19: 21652170.
  • 46
    Kami M, Machida U, Okuzumi K, et al. Effect of fluconazole prophylaxis on fungal blood cultures: an autopsy-based study involving 720 patients with haematological malignancy. Br J Haematol. 2002; 117: 4046.
  • 47
    Krcmery V Jr., Mrazova M, Kunova A, et al. Nosocomial candidaemias due to species other than Candida albicans in cancer patients. Aetiology, risk factors, and outcome of 45 episodes within 10 years in a single cancer institution. Support Care Cancer. 1999; 7: 428431.
  • 48
    Kontoyiannis DP, Bodey GP. Invasive aspergillosis in 2002: an update. Eur J Clin Microbiol Infect Dis. 2002; 21: 161172.
  • 49
    Giles FJ. Monocyte-macrophages, granulocyte-macrophage colony-stimulating factor, and prolonged survival among patients with acute myeloid leukemia and stem cell transplants. Clin Infect Dis. 1998; 26: 12821289.
  • 50
    Peters BG, Adkins DR, Harrison BR, et al. Antifungal effects of yeast-derived rhu-GM-CSF in patients receiving high-dose chemotherapy given with or without autologous stem cell transplantation: a retrospective analysis. Bone Marrow Transplant. 1996; 18: 93102.
  • 51
    Rowe JM, Andersen JW, Mazza JJ, et al. A randomized placebo-controlled Phase III study of granulocyte-macrophage colony-stimulating factor in adult patients (> 55 to 70 years of age) with acute myelogenous leukemia: a study of the Eastern Cooperative Oncology Group (E1490). Blood. 1995; 86: 457462.
  • 52
    Verbeek W, Wormann B, Koch P, et al. Results of a randomized double-blind placebo-controlled trial evaluating sequential high-dose cytosine arabinoside/mitoxantrone chemotherapy with or without granulocyte/macrophage-colony-stimulating factor in high-risk myelodysplastic syndromes. J Cancer Res Clin Oncol. 1999; 125: 369374.
  • 53
    Lowenberg B, Suciu S, Archimbaud E, et al. Use of recombinant GM-CSF during and after remission induction chemotherapy in patients aged 61 years and older with acute myeloid leukemia: final report of AML-11, a Phase III randomized study of the Leukemia Cooperative Group of European Organisation for the Research and Treatment of Cancer and the Dutch Belgian Hemato-Oncology Cooperative Group. Blood. 1997; 90: 29522961.
  • 54
    Han T, Sadamori N, Block AM, et al. Cytogenetic studies in chronic lymphocytic leukemia, prolymphocytic leukemia and hairy cell leukemia: a progress report. Nouv Rev Fr Hematol. 1988; 30: 393395.